Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Immatics N.V. (IMTX) vs Ultragenyx Pharmaceutical Inc. (RARE)

Immatics N.V. and Ultragenyx Pharmaceutical Inc. are both Biotechnology companies. Ultragenyx Pharmaceutical Inc. is the larger, with a market value of $1.5B against $1.3B — 1.2× the size. Ultragenyx Pharmaceutical Inc. grew revenue faster over the last twelve months: 17.5% against −65.0%. Ultragenyx Pharmaceutical Inc. has the higher net margin (−81.7% vs −489.4%) and the higher return on invested capital (0.00% vs −84.8%). Across the 16 metrics below, Ultragenyx Pharmaceutical Inc. leads on 11 and Immatics N.V. on 5.

Valuation

Metric IMTX RARE Biotechnology median
P/E n/m n/m 7.88
P/S 23.25 2.06 11.47
P/B 2.46 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 17.76 1.65 10.73
Earnings yield (22.22%) (40.28%) (28.84%)
Free cash flow yield (21.01%) (33.43%) (23.03%)

Profitability

Metric IMTX RARE Biotechnology median
Gross margin 100.00% 83.12% 65.16%
Operating margin (536.26%) (73.64%) 0.00%
Net margin (489.35%) (81.73%) 0.00%
Free cash flow margin (488.01%) (68.90%) 0.00%
Return on equity (48.53%) 838.86% (57.72%)
Return on assets (39.83%) (45.60%) (49.22%)
Return on invested capital (84.83%) 0.00% 0.00%

Growth

Metric IMTX RARE Biotechnology median
Revenue growth (TTM) (64.99%) 17.51% 5.64%
EPS growth (last fiscal year) (1,313.33%) 7.31% —
Revenue growth, 5-year CAGR 11.81% 19.95% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMTX RARE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.54 1.73 4.73
Net debt to EBITDA 2.04 1.35 0.96

Dividend

Metric IMTX RARE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IMTX RARE Biotechnology median
Market cap 1.26b 1.45b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack